News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics



1/25/2013 6:00:14 AM

Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company's prototype insulin sensitizer in patients diagnosed with type 2 diabetes. The data demonstrate MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators™, met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c).

Read at Sacramento Bee


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES